1. Home
  2. TBPH vs RCAT Comparison

TBPH vs RCAT Comparison

Compare TBPH & RCAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$20.04

Market Cap

993.7M

Sector

Health Care

ML Signal

HOLD

Logo Red Cat Holdings Inc.

RCAT

Red Cat Holdings Inc.

HOLD

Current Price

$13.72

Market Cap

957.4M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
TBPH
RCAT
Founded
2013
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Wholesale Distributors
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
993.7M
957.4M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
TBPH
RCAT
Price
$20.04
$13.72
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
2
Target Price
$27.80
$14.50
AVG Volume (30 Days)
439.2K
12.8M
Earning Date
02-25-2026
02-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.58
N/A
Revenue
$80,327,000.00
$7,443,942.00
Revenue This Year
$70.78
$396.50
Revenue Next Year
N/A
$296.06
P/E Ratio
$34.48
N/A
Revenue Growth
27.12
N/A
52 Week Low
$7.90
$4.58
52 Week High
$20.79
$16.70

Technical Indicators

Market Signals
Indicator
TBPH
RCAT
Relative Strength Index (RSI) 62.84 72.77
Support Level $18.41 $11.43
Resistance Level $20.79 $14.65
Average True Range (ATR) 0.71 1.14
MACD 0.12 0.47
Stochastic Oscillator 76.62 86.70

Price Performance

Historical Comparison
TBPH
RCAT

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About RCAT Red Cat Holdings Inc.

Red Cat Holdings Inc is a drone technology company integrating robotic hardware and software for military, government, and commercial operations. Red Cat's suite of solutions includes the Arachnid family of ISR and precision strike drones, which includes the Black Widow, a small unmanned ISR system; and WEB (Warfighter Electronic Bridge) GCS, designed to command and control an entire drone family of systems for military operations. Its other offerings include Edge 130 Blue drone systems, Trichon, a fixed-wing VTOL for extended endurance and range, and FANG FPV drones optimized for military operations with precision strike capabilities.

Share on Social Networks: